Katherine K. Nishimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katherine K. Nishimura has a total of 440 co-authors. Here are the top co-authors by number of shared publications:
- Antje Hoering
Cancer Research and Biostatistics, Seattle, WA
9 shared publications - Diana Merino Vega
Translational Medicine, Cancer Biomarker Development, Oncology R&D, AstraZeneca, Gaithersburg, MD
9 shared publications - Jeff Allen
Friends of Cancer Research, Washington, DC
9 shared publications - Mark Stewart
Friends of Cancer Research, Washington, DC
9 shared publications - Nevine Zariffa
NMD Group Inc., Bala Cynwyd, Pennsylvania
9 shared publications - Adam Rosenthal
Cancer Research and Biostatistics, Seattle, Washington
8 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Figure S3. Kaplan-Meier Curves for OS and PFS by Baseline ctDNA Detection and Multivariable Associations. Kaplan-Meier plot for (A) OS and (B) PFS and baseline ctDNA detection vs. non-detection, landmarked at 70 days from index; patients with an event during the 70-day landmark were excluded from the analysis. Data presented include the Training and Test datasets.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Figure S3. Kaplan-Meier Curves for OS and PFS by Baseline ctDNA Detection and Multivariable Associations. Kaplan-Meier plot for (A) OS and (B) PFS and baseline ctDNA detection vs. non-detection, landmarked at 70 days from index; patients with an event during the 70-day landmark were excluded from the analysis. Data presented include the Training and Test datasets.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Figure S4. Kaplan-Meier Curves for OS and PFS by Baseline ctDNA Detection and Multivariable Associations. Kaplan-Meier plot for (A) OS and (B) PFS and baseline ctDNA detection vs. non-detection, landmarked at 70 days from index; patients with an event during the 70-day landmark were excluded from the analysis. Data presented include the Training and Test datasets.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Figure S4. Kaplan-Meier Curves for OS and PFS by Baseline ctDNA Detection and Multivariable Associations. Kaplan-Meier plot for (A) OS and (B) PFS and baseline ctDNA detection vs. non-detection, landmarked at 70 days from index; patients with an event during the 70-day landmark were excluded from the analysis. Data presented include the Training and Test datasets.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Figure S1. Kaplan-Meier Curves for OS and PFS by Percent Change in ctDNA Levels and Multivariable Associations. Kaplan-Meier plot for (A) OS and (B) PFS and percent change in ctDNA levels from T0 to T1, landmarked at 70 days from index; patients with an event during the 70-day landmark were excluded from the analysis. Data presented include the Training dataset only.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Figure S1. Kaplan-Meier Curves for OS and PFS by Percent Change in ctDNA Levels and Multivariable Associations. Kaplan-Meier plot for (A) OS and (B) PFS and percent change in ctDNA levels from T0 to T1, landmarked at 70 days from index; patients with an event during the 70-day landmark were excluded from the analysis. Data presented include the Training dataset only.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Figure S2. Comparison of Training vs. Test Datasets for Research Objective 1. Training (A,B) vs. test (C,D) datasets for research objective 1. For OS, the multivariable Harrel’s C-Index for Training was 0.749 and for Test was 0.697 while the Uno’s C-Index was 0.736 for Training and 0.645 for Test. For PFS, the multivariable Harrel’s C-Index for Training was 0.653 and for Test was 0.599 while the multivariable Uno’s C-Index was 0.630 for Training and 0.589 for Test.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Figure S2. Comparison of Training vs. Test Datasets for Research Objective 1. Training (A,B) vs. test (C,D) datasets for research objective 1. For OS, the multivariable Harrel’s C-Index for Training was 0.749 and for Test was 0.697 while the Uno’s C-Index was 0.736 for Training and 0.645 for Test. For PFS, the multivariable Harrel’s C-Index for Training was 0.653 and for Test was 0.599 while the multivariable Uno’s C-Index was 0.630 for Training and 0.589 for Test.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Figure S6. Training vs. Test Datasets for Early Radiographic Response Combined with ctDNA Categories. Training (A,B) vs. Test (C,D) datasets for early radiographic response combined with ctDNA categories. For OS, the multivariable Harrel’s C-Index for Training was 0.753 and for Test was 0.723 while the Uno’s C-Index was 0.744 for Training and 0.660 for Test. For PFS, the multivariable Harrel’s C-Index for Training was 0.649 and for Test was 0.603 while the Uno’s C-Index was 0.646 for Training and 0.595 for Test.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Figure S6. Training vs. Test Datasets for Early Radiographic Response Combined with ctDNA Categories. Training (A,B) vs. Test (C,D) datasets for early radiographic response combined with ctDNA categories. For OS, the multivariable Harrel’s C-Index for Training was 0.753 and for Test was 0.723 while the Uno’s C-Index was 0.744 for Training and 0.660 for Test. For PFS, the multivariable Harrel’s C-Index for Training was 0.649 and for Test was 0.603 while the Uno’s C-Index was 0.646 for Training and 0.595 for Test.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Figure S5. Training vs. Test Datasets for Early Radiographic Response and OS/PFS. Training (A,B) vs. Test (C,D) datasets for early radiographic response. For OS focused on early radiographic response, the multivariable Harrel’s C-Index for Training was 0.695 and for Test was 0.688 while the Uno’s C-Index was 0.708 for Training and 0.661 for Test. For PFS focused on early radiographic response, the multivariable Harrel’s C-Index for Training was 0.621 and for Test was 0.541 while the Uno’s C-Index was 0.623 for Training and 0.535 for Test.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Figure S5. Training vs. Test Datasets for Early Radiographic Response and OS/PFS. Training (A,B) vs. Test (C,D) datasets for early radiographic response. For OS focused on early radiographic response, the multivariable Harrel’s C-Index for Training was 0.695 and for Test was 0.688 while the Uno’s C-Index was 0.708 for Training and 0.661 for Test. For PFS focused on early radiographic response, the multivariable Harrel’s C-Index for Training was 0.621 and for Test was 0.541 while the Uno’s C-Index was 0.623 for Training and 0.535 for Test.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Table S1. Clinical trials included in the analysis. This table summarizes the clinical trials included in the analysis, detailing the study name, sponsor, trial type, tumor type, treatment, and ctDNA assay used. References to the original trial publications are also provided.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Supplementary Table S1. Clinical trials included in the analysis. This table summarizes the clinical trials included in the analysis, detailing the study name, sponsor, trial type, tumor type, treatment, and ctDNA assay used. References to the original trial publications are also provided.
- Open Access
- 22 April 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (11) , 2162-2172
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Purpose: Circulating tumor DNA (ctDNA) holds promise as an early endpoint to predict overall survival (OS). The creation and structured interrogation of aggregated datasets inform the hypothesis that ctDNA is reasonably likely to predict treatment benefit. Friends of Cancer Research convened a diverse working group to establish and implement an analysis plan assessing patient-level associations between changes in ctDNA levels with OS and progression-free survival (PFS). Experimental Design: The aggregate dataset included eight clinical trials representing 940 patients with biomarker-positive advanced non–small cell lung cancer treated with tyrosine kinase inhibitors. Detection of baseline and on-treatment ctDNA was assessed for associations with OS and PFS. Additionally, combinations of ctDNA detection and RECIST measurements up to 10 weeks on treatment were considered. Results: Patients with detected ctDNA at baseline that became nondetected on treatment (“clearance”) experienced improved OS compared with patients with persistently detected ctDNA (adjusted HR = 2.12, P < 0.001). This pattern was also seen in the subset of patients with stable disease as measured by RECIST within 10 weeks of treatment initiation (adjusted HR = 4.15, P < 0.001). Results were similar for PFS. Conclusions: In patients with oncogene-driven advanced non–small cell lung cancer treated with tyrosine kinase inhibitors, ctDNA clearance within 10 weeks of treatment initiation was associated with improved OS and PFS. These patient-level results support the growing evidence that demonstrates a change in ctDNA levels during treatment is associated with clinical benefit. Future prospective trials should include predefined thresholds of molecular response to advance the utility of ctDNA as an early endpoint.
- 22 April 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (11) , 2162-2172
Open AccessctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Purpose: Circulating tumor DNA (ctDNA) holds promise as an early endpoint to predict overall survival (OS). The creation and structured interrogation of aggregated datasets inform the hypothesis that ctDNA is reasonably likely to predict treatment benefit. Friends of Cancer Research convened a diverse working group to establish and implement an analysis plan assessing patient-level associations between changes in ctDNA levels with OS and progression-free survival (PFS). Experimental Design: The aggregate dataset included eight clinical trials representing 940 patients with biomarker-positive advanced non–small cell lung cancer treated with tyrosine kinase inhibitors. Detection of baseline and on-treatment ctDNA was assessed for associations with OS and PFS. Additionally, combinations of ctDNA detection and RECIST measurements up to 10 weeks on treatment were considered. Results: Patients with detected ctDNA at baseline that became nondetected on treatment (“clearance”) experienced improved OS compared with patients with persistently detected ctDNA (adjusted HR = 2.12, P < 0.001). This pattern was also seen in the subset of patients with stable disease as measured by RECIST within 10 weeks of treatment initiation (adjusted HR = 4.15, P < 0.001). Results were similar for PFS. Conclusions: In patients with oncogene-driven advanced non–small cell lung cancer treated with tyrosine kinase inhibitors, ctDNA clearance within 10 weeks of treatment initiation was associated with improved OS and PFS. These patient-level results support the growing evidence that demonstrates a change in ctDNA levels during treatment is associated with clinical benefit. Future prospective trials should include predefined thresholds of molecular response to advance the utility of ctDNA as an early endpoint.
- Open Access
- 11 August 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 6 (6) , e2100372
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
PURPOSE: As immune checkpoint inhibitors (ICI) become increasingly used in frontline settings, identifying early indicators of response is needed. Recent studies suggest a role for circulating tumor DNA (ctDNA) in monitoring response to ICI, but uncertainty exists in the generalizability of these studies. Here, the role of ctDNA for monitoring response to ICI is assessed through a standardized approach by assessing clinical trial data from five independent studies. PATIENTS AND METHODS: Patient-level clinical and ctDNA data were pooled and harmonized from 200 patients across five independent clinical trials investigating the treatment of patients with non–small-cell lung cancer with programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)–directed monotherapy or in combination with chemotherapy. CtDNA levels were measured using different ctDNA assays across the studies. Maximum variant allele frequencies were calculated using all somatic tumor-derived variants in each unique patient sample to correlate ctDNA changes with overall survival (OS) and progression-free survival (PFS). RESULTS: We observed strong associations between reductions in ctDNA levels from on-treatment liquid biopsies with improved OS (OS; hazard ratio, 2.28; 95% CI, 1.62 to 3.20; P < .001) and PFS (PFS; hazard ratio 1.76; 95% CI, 1.31 to 2.36; P < .001). Changes in the maximum variant allele frequencies ctDNA values showed strong association across different outcomes. CONCLUSION: In this pooled analysis of five independent clinical trials, consistent and robust associations between reductions in ctDNA and outcomes were found across multiple end points assessed in patients with non–small-cell lung cancer treated with an ICI. Additional tumor types, stages, and drug classes should be included in future analyses to further validate this. CtDNA may serve as an important tool in clinical development and an early indicator of treatment benefit.
- 11 August 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 6 (6) , e2100372
Open AccessChanges in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
PURPOSE: As immune checkpoint inhibitors (ICI) become increasingly used in frontline settings, identifying early indicators of response is needed. Recent studies suggest a role for circulating tumor DNA (ctDNA) in monitoring response to ICI, but uncertainty exists in the generalizability of these studies. Here, the role of ctDNA for monitoring response to ICI is assessed through a standardized approach by assessing clinical trial data from five independent studies. PATIENTS AND METHODS: Patient-level clinical and ctDNA data were pooled and harmonized from 200 patients across five independent clinical trials investigating the treatment of patients with non–small-cell lung cancer with programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)–directed monotherapy or in combination with chemotherapy. CtDNA levels were measured using different ctDNA assays across the studies. Maximum variant allele frequencies were calculated using all somatic tumor-derived variants in each unique patient sample to correlate ctDNA changes with overall survival (OS) and progression-free survival (PFS). RESULTS: We observed strong associations between reductions in ctDNA levels from on-treatment liquid biopsies with improved OS (OS; hazard ratio, 2.28; 95% CI, 1.62 to 3.20; P < .001) and PFS (PFS; hazard ratio 1.76; 95% CI, 1.31 to 2.36; P < .001). Changes in the maximum variant allele frequencies ctDNA values showed strong association across different outcomes. CONCLUSION: In this pooled analysis of five independent clinical trials, consistent and robust associations between reductions in ctDNA and outcomes were found across multiple end points assessed in patients with non–small-cell lung cancer treated with an ICI. Additional tumor types, stages, and drug classes should be included in future analyses to further validate this. CtDNA may serve as an important tool in clinical development and an early indicator of treatment benefit.
- Open Access
- 30 March 2020
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 16 (3) , e1008684
Minority-centric meta-analyses of blood lipid levels identify novel loci in the Population Architecture using Genomics and Epidemiology (PAGE) study
Lipid levels are important markers for the development of cardio-metabolic diseases. Although hundreds of associated loci have been identified through genetic association studies, the contribution of genetic factors to variation in lipids is not fully understood, particularly in U.S. minority groups. We performed genome-wide association analyses for four lipid traits in over 45,000 ancestrally diverse participants from the Population Architecture using Genomics and Epidemiology (PAGE) Study, followed by a meta-analysis with several European ancestry studies. We identified nine novel lipid loci, five of which showed evidence of replication in independent studies. Furthermore, we discovered one novel gene in a PrediXcan analysis, minority-specific independent signals at eight previously reported loci, and potential functional variants at two known loci through fine-mapping. Systematic examination of known lipid loci revealed smaller effect estimates in African American and Hispanic ancestry populations than those in Europeans, and better performance of polygenic risk scores based on minority-specific effect estimates. Our findings provide new insight into the genetic architecture of lipid traits and highlight the importance of conducting genetic studies in diverse populations in the era of precision medicine. Blood lipid levels are closely linked to cardio-metabolic diseases, and genetic factors play an important role in their metabolism and regulation. Although over 400 loci have been identified through genetic association studies, the genetic architecture of lipid levels is not fully characterized. The lack of representation of diverse populations in previous studies resulted in a large gap in understanding the genetic background of lipid traits between European and minority populations, including African Americans, Hispanics, Hawaiians, and Native Americans. In our current analyses which included ancestrally diverse populations, we identified nine novel loci, one novel gene, and minority-specific independent signals at eight known loci, and pinpointed potential functional variants at two known loci. We further observed smaller effect sizes of reported lipids-associated loci in African Americans and Hispanics than those in Europeans, and better performance of polygenic risk scores using minority-specific instead of European-derived effect sizes when estimating genetic predisposition in minority populations. Our findings showed the benefits of including multi-ethnic studies in identification and refinement of lipids-associated loci, which will help to reduce the existing disparities and to pave the road to precision medicine.
- 30 March 2020
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 16 (3) , e1008684
Open AccessMinority-centric meta-analyses of blood lipid levels identify novel loci in the Population Architecture using Genomics and Epidemiology (PAGE) study
Lipid levels are important markers for the development of cardio-metabolic diseases. Although hundreds of associated loci have been identified through genetic association studies, the contribution of genetic factors to variation in lipids is not fully understood, particularly in U.S. minority groups. We performed genome-wide association analyses for four lipid traits in over 45,000 ancestrally diverse participants from the Population Architecture using Genomics and Epidemiology (PAGE) Study, followed by a meta-analysis with several European ancestry studies. We identified nine novel lipid loci, five of which showed evidence of replication in independent studies. Furthermore, we discovered one novel gene in a PrediXcan analysis, minority-specific independent signals at eight previously reported loci, and potential functional variants at two known loci through fine-mapping. Systematic examination of known lipid loci revealed smaller effect estimates in African American and Hispanic ancestry populations than those in Europeans, and better performance of polygenic risk scores based on minority-specific effect estimates. Our findings provide new insight into the genetic architecture of lipid traits and highlight the importance of conducting genetic studies in diverse populations in the era of precision medicine. Blood lipid levels are closely linked to cardio-metabolic diseases, and genetic factors play an important role in their metabolism and regulation. Although over 400 loci have been identified through genetic association studies, the genetic architecture of lipid levels is not fully characterized. The lack of representation of diverse populations in previous studies resulted in a large gap in understanding the genetic background of lipid traits between European and minority populations, including African Americans, Hispanics, Hawaiians, and Native Americans. In our current analyses which included ancestrally diverse populations, we identified nine novel loci, one novel gene, and minority-specific independent signals at eight known loci, and pinpointed potential functional variants at two known loci. We further observed smaller effect sizes of reported lipids-associated loci in African Americans and Hispanics than those in Europeans, and better performance of polygenic risk scores using minority-specific instead of European-derived effect sizes when estimating genetic predisposition in minority populations. Our findings showed the benefits of including multi-ethnic studies in identification and refinement of lipids-associated loci, which will help to reduce the existing disparities and to pave the road to precision medicine.